But Phase I clinical trials revealed that while the drug wasn’t great at treating what it was supposed to treat, male test subjects were experiencing a rather unexpected side effect: erections.
A few years later, in 1998, the drug took U.S. markets by storm as a treatment for penile dysfunction and became an overnight success.
It now rakes in an estimated $1.9 billion a year.
